2023-05-09 07:34:51 ET
- Anavex Life Sciences press release ( NASDAQ: AVXL ): Q2 GAAP EPS of -$0.17 beats by $0.01 .
- Cash and cash equivalents of $153.5 million at March 31, 2023 compared to $149.2 million at year end September 30, 2022.
- Newly available preliminary efficacy results of surrogate biomarkers from the ANAVEX®2-73-AD-004 study; allowing initiation of discussions with regulatory agencies for Accelerated Approval Pathway for ANAVEX®2-73 (blarcamesine) in Alzheimer’s disease with convenient oral treatment
- On track to release top-line data of potentially pivotal ANAVEX®2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial in the second half of 2023.
- Shares +0.71% PM.
For further details see:
Anavex Life Sciences GAAP EPS of -$0.17 beats by $0.01